Halozyme Therapeutics, Inc. (NASDAQ: HALO) Stock Competitors & Peer Comparison
See HALO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HALO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HALO | $82.54 | -0.91% | 9.8B | 17.87 | $4.62 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
HALO vs VRTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas VRTX's P/E ratio is 25.35. In terms of profitability, HALO's ROE is +1.26%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, HALO is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
HALO vs REGN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas REGN's P/E ratio is 16.71. In terms of profitability, HALO's ROE is +1.26%, compared to REGN's ROE of +0.18%. Regarding short-term risk, HALO is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for HALO.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
HALO vs VRNA Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, HALO's ROE is +1.26%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, HALO is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for HALO.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
HALO vs ARGX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ARGX's P/E ratio is 78.75. In terms of profitability, HALO's ROE is +1.26%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, HALO is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
HALO vs SGEN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, HALO's ROE is +1.26%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, HALO is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
HALO vs RVMDW Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, HALO's ROE is +1.26%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, HALO is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
HALO vs RVMD Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RVMD's P/E ratio is -26.52. In terms of profitability, HALO's ROE is +1.26%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, HALO is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for HALO.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
HALO vs ONC Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ONC's P/E ratio is 70.70. In terms of profitability, HALO's ROE is +1.26%, compared to ONC's ROE of +0.12%. Regarding short-term risk, HALO is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
HALO vs ALNY Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ALNY's P/E ratio is 37.02. In terms of profitability, HALO's ROE is +1.26%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, HALO is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
HALO vs ROIV Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ROIV's P/E ratio is -34.86. In terms of profitability, HALO's ROE is +1.26%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, HALO is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
HALO vs INCY Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas INCY's P/E ratio is 16.06. In terms of profitability, HALO's ROE is +1.26%, compared to INCY's ROE of +0.30%. Regarding short-term risk, HALO is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for HALO.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
HALO vs BNTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas BNTX's P/E ratio is -19.61. In terms of profitability, HALO's ROE is +1.26%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, HALO is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
HALO vs UTHR Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas UTHR's P/E ratio is 19.10. In terms of profitability, HALO's ROE is +1.26%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, HALO is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for HALO.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
HALO vs MRNA Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas MRNA's P/E ratio is -6.73. In terms of profitability, HALO's ROE is +1.26%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, HALO is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
HALO vs INSM Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas INSM's P/E ratio is -17.15. In terms of profitability, HALO's ROE is +1.26%, compared to INSM's ROE of -1.30%. Regarding short-term risk, HALO is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
HALO vs BGNE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, HALO's ROE is +1.26%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, HALO is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
HALO vs DNA-WT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, HALO's ROE is +1.26%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, HALO is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
HALO vs GMAB Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas GMAB's P/E ratio is 20.77. In terms of profitability, HALO's ROE is +1.26%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, HALO is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for HALO.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
HALO vs NBIX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas NBIX's P/E ratio is 24.10. In terms of profitability, HALO's ROE is +1.26%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, HALO is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
HALO vs JAZZ Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, HALO's ROE is +1.26%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, HALO is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for HALO.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
HALO vs BBIO Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas BBIO's P/E ratio is -21.41. In terms of profitability, HALO's ROE is +1.26%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, HALO is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for HALO.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
HALO vs ASND Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ASND's P/E ratio is -100.79. In terms of profitability, HALO's ROE is +1.26%, compared to ASND's ROE of -56.42%. Regarding short-term risk, HALO is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
HALO vs EXEL Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas EXEL's P/E ratio is 15.88. In terms of profitability, HALO's ROE is +1.26%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, HALO is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for HALO.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
HALO vs KRTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, HALO's ROE is +1.26%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, HALO is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
HALO vs ARWR Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ARWR's P/E ratio is -39.37. In terms of profitability, HALO's ROE is +1.26%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, HALO is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
HALO vs BMRN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas BMRN's P/E ratio is 28.86. In terms of profitability, HALO's ROE is +1.26%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, HALO is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for HALO.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
HALO vs TECH Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas TECH's P/E ratio is 37.16. In terms of profitability, HALO's ROE is +1.26%, compared to TECH's ROE of +0.05%. Regarding short-term risk, HALO is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for HALO.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
HALO vs RNAM Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, HALO's ROE is +1.26%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, HALO is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
HALO vs AXSM Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas AXSM's P/E ratio is -56.92. In terms of profitability, HALO's ROE is +1.26%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, HALO is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
HALO vs MDGL Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas MDGL's P/E ratio is -36.51. In terms of profitability, HALO's ROE is +1.26%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, HALO is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
HALO vs SMMT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas SMMT's P/E ratio is -8.14. In terms of profitability, HALO's ROE is +1.26%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, HALO is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
HALO vs KRYS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas KRYS's P/E ratio is 45.60. In terms of profitability, HALO's ROE is +1.26%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, HALO is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check KRYS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
HALO vs CYTK Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CYTK's P/E ratio is -13.23. In terms of profitability, HALO's ROE is +1.26%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, HALO is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
HALO vs RXDX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, HALO's ROE is +1.26%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, HALO is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
HALO vs ABVX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ABVX's P/E ratio is -65.48. In terms of profitability, HALO's ROE is +1.26%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, HALO is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
HALO vs NUVL Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas NUVL's P/E ratio is -21.79. In terms of profitability, HALO's ROE is +1.26%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, HALO is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for HALO.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
HALO vs CRNX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CRNX's P/E ratio is -16.28. In terms of profitability, HALO's ROE is +1.26%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, HALO is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
HALO vs PTGX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas PTGX's P/E ratio is -75.49. In terms of profitability, HALO's ROE is +1.26%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, HALO is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
HALO vs IMGN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, HALO's ROE is +1.26%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, HALO is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
HALO vs IONS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas IONS's P/E ratio is -30.10. In terms of profitability, HALO's ROE is +1.26%, compared to IONS's ROE of -1.11%. Regarding short-term risk, HALO is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
HALO vs PRAX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas PRAX's P/E ratio is -23.02. In terms of profitability, HALO's ROE is +1.26%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, HALO is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
HALO vs SYRE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas SYRE's P/E ratio is -47.27. In terms of profitability, HALO's ROE is +1.26%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, HALO is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
HALO vs KYMR Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas KYMR's P/E ratio is -29.29. In terms of profitability, HALO's ROE is +1.26%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, HALO is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for HALO.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
HALO vs ALKS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ALKS's P/E ratio is 52.66. In terms of profitability, HALO's ROE is +1.26%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, HALO is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
HALO vs BPMC Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, HALO's ROE is +1.26%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, HALO is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for HALO.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
HALO vs APGE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas APGE's P/E ratio is -30.97. In terms of profitability, HALO's ROE is +1.26%, compared to APGE's ROE of -0.33%. Regarding short-term risk, HALO is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
HALO vs CERE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, HALO's ROE is +1.26%, compared to CERE's ROE of -0.72%. Regarding short-term risk, HALO is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
HALO vs TGTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas TGTX's P/E ratio is 17.88. In terms of profitability, HALO's ROE is +1.26%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, HALO is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
HALO vs IMVT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas IMVT's P/E ratio is -14.46. In terms of profitability, HALO's ROE is +1.26%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, HALO is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
HALO vs PCVX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas PCVX's P/E ratio is -7.86. In terms of profitability, HALO's ROE is +1.26%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, HALO is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
HALO vs IBRX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas IBRX's P/E ratio is -8.44. In terms of profitability, HALO's ROE is +1.26%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, HALO is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
HALO vs MTSR Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, HALO's ROE is +1.26%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, HALO is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for HALO.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
HALO vs MRUS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, HALO's ROE is +1.26%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, HALO is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for HALO.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
HALO vs RYTM Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RYTM's P/E ratio is -31.71. In terms of profitability, HALO's ROE is +1.26%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, HALO is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
HALO vs ACLX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, HALO's ROE is +1.26%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, HALO is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
HALO vs COGT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas COGT's P/E ratio is -18.45. In terms of profitability, HALO's ROE is +1.26%, compared to COGT's ROE of -0.83%. Regarding short-term risk, HALO is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
HALO vs RETA Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, HALO's ROE is +1.26%, compared to RETA's ROE of +0.47%. Regarding short-term risk, HALO is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
HALO vs MIRM Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas MIRM's P/E ratio is -7.78. In terms of profitability, HALO's ROE is +1.26%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, HALO is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
HALO vs BLTE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas BLTE's P/E ratio is -84.82. In terms of profitability, HALO's ROE is +1.26%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, HALO is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
HALO vs ERAS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ERAS's P/E ratio is -19.51. In terms of profitability, HALO's ROE is +1.26%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, HALO is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
HALO vs CGON Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CGON's P/E ratio is -30.55. In terms of profitability, HALO's ROE is +1.26%, compared to CGON's ROE of -0.23%. Regarding short-term risk, HALO is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
HALO vs CNTA Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CNTA's P/E ratio is -22.63. In terms of profitability, HALO's ROE is +1.26%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, HALO is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
HALO vs XENE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas XENE's P/E ratio is -13.33. In terms of profitability, HALO's ROE is +1.26%, compared to XENE's ROE of -0.49%. Regarding short-term risk, HALO is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
HALO vs LGND Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas LGND's P/E ratio is 34.48. In terms of profitability, HALO's ROE is +1.26%, compared to LGND's ROE of +0.16%. Regarding short-term risk, HALO is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for HALO.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
HALO vs SRRK Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas SRRK's P/E ratio is -13.17. In terms of profitability, HALO's ROE is +1.26%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, HALO is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for HALO.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
HALO vs PTCT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas PTCT's P/E ratio is -29.19. In terms of profitability, HALO's ROE is +1.26%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, HALO is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
HALO vs CDTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, HALO's ROE is +1.26%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, HALO is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
HALO vs ABCM Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, HALO's ROE is +1.26%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, HALO is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
HALO vs ISEE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, HALO's ROE is +1.26%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, HALO is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
HALO vs APLS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, HALO's ROE is +1.26%, compared to APLS's ROE of +0.40%. Regarding short-term risk, HALO is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for HALO.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
HALO vs TVTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas TVTX's P/E ratio is -254.05. In terms of profitability, HALO's ROE is +1.26%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, HALO is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
HALO vs TERN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, HALO's ROE is +1.26%, compared to TERN's ROE of -0.20%. Regarding short-term risk, HALO is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
HALO vs DFTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas DFTX's P/E ratio is N/A. In terms of profitability, HALO's ROE is +1.26%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, HALO is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
HALO vs DYN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas DYN's P/E ratio is -7.82. In terms of profitability, HALO's ROE is +1.26%, compared to DYN's ROE of -0.64%. Regarding short-term risk, HALO is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
HALO vs CRSP Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CRSP's P/E ratio is -9.39. In terms of profitability, HALO's ROE is +1.26%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, HALO is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
HALO vs FOLD Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, HALO's ROE is +1.26%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, HALO is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for HALO.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
HALO vs AKRO Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, HALO's ROE is +1.26%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, HALO is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for HALO.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
HALO vs DNTH Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas DNTH's P/E ratio is -25.89. In terms of profitability, HALO's ROE is +1.26%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, HALO is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
HALO vs ALPN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, HALO's ROE is +1.26%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, HALO is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
HALO vs ACAD Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ACAD's P/E ratio is 12.68. In terms of profitability, HALO's ROE is +1.26%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, HALO is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
HALO vs CAI Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CAI's P/E ratio is -86.19. In terms of profitability, HALO's ROE is +1.26%, compared to CAI's ROE of +0.06%. Regarding short-term risk, HALO is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
HALO vs MANE Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas MANE's P/E ratio is -33.36. In terms of profitability, HALO's ROE is +1.26%, compared to MANE's ROE of -0.84%. Regarding short-term risk, HALO is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
HALO vs OPT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, HALO's ROE is +1.26%, compared to OPT's ROE of +1.18%. Regarding short-term risk, HALO is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for HALO.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
HALO vs PRTC Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas PRTC's P/E ratio is -3.78. In terms of profitability, HALO's ROE is +1.26%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, HALO is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
HALO vs CELC Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CELC's P/E ratio is -22.15. In terms of profitability, HALO's ROE is +1.26%, compared to CELC's ROE of -2.45%. Regarding short-term risk, HALO is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
HALO vs EWTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas EWTX's P/E ratio is -23.15. In terms of profitability, HALO's ROE is +1.26%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, HALO is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
HALO vs MRTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, HALO's ROE is +1.26%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, HALO is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
HALO vs ELVN Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ELVN's P/E ratio is -32.82. In terms of profitability, HALO's ROE is +1.26%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, HALO is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
HALO vs CPRX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CPRX's P/E ratio is 12.30. In terms of profitability, HALO's ROE is +1.26%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, HALO is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
HALO vs RYZB Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, HALO's ROE is +1.26%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, HALO is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
HALO vs CBAY Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, HALO's ROE is +1.26%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, HALO is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
HALO vs VKTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas VKTX's P/E ratio is -7.67. In terms of profitability, HALO's ROE is +1.26%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, HALO is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
HALO vs DNLI Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas DNLI's P/E ratio is -7.99. In terms of profitability, HALO's ROE is +1.26%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, HALO is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
HALO vs ORKA Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ORKA's P/E ratio is -49.75. In terms of profitability, HALO's ROE is +1.26%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, HALO is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
HALO vs ADPT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ADPT's P/E ratio is -41.80. In terms of profitability, HALO's ROE is +1.26%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, HALO is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
HALO vs ALMS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ALMS's P/E ratio is -7.39. In terms of profitability, HALO's ROE is +1.26%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, HALO is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
HALO vs RCUS Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas RCUS's P/E ratio is -8.66. In terms of profitability, HALO's ROE is +1.26%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, HALO is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
HALO vs SWTX Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas SWTX's P/E ratio is -13.78. In terms of profitability, HALO's ROE is +1.26%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, HALO is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
HALO vs ARQT Comparison August 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 9.8B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, HALO is priced at $82.54 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 17.87, whereas ARQT's P/E ratio is -933.00. In terms of profitability, HALO's ROE is +1.26%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, HALO is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ARQT's competition here